CxTx will develop and partner connexin inhibitors for retinal neuroprotection.

We are seeking financing to undertake a connexin inhibitor drug discovery and development program.

Our initial tranche will focus on the in silico modeling, synthesis, and screening of Cx36 and Cx45 inhibitors with oral bioavailability.

Such compounds could form the basis of early-stage partnerships with multinational pharmaceutical companies.